Position statement of the Slovenian society of anaesthesiology and intensive care medicine on the use of sugammadex
Abstract
We present our position statement for the use of sugammadex, a specific binder for aminosteroid muscle relaxants, in the most common clinical circumstances (in the case of an emergency intubation, when the patient cannot be ventilated or intubated; in patients with neuro-muscular disease, in patients with liver failure, in patients with renal failure, in patients with allergic reaction to sugammadex or to rocuronium, in cases of residual muscle relaxation and when we have to use a muscle relaxant short time after sugammadex application). Sugammadex is the drug of choice in cases of cardiac arhythmia, COPD, asthma, neuro-muscular diseases, pathological obesity, intraoperative use of continuous infusion of aminoglycoside muscle relaxants. It is therefore necessary to control the neuro-muscular block during surgery due to different response of patients to the muscle relaxant. Clinical tests alone are not an adequate substitute for objective control of muscular strength recovery.
Downloads
References
Lemmens HJ, El-Orbany MI, Berry J, Morte JB Jr, Martin G. Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine. BMC Anesthesiol. 2010 Sep;10(1):15. https://doi.org/10.1186/1471-2253-10-15 PMID:20809967
Ogunnaike BO, Jones SB, Jones DB, Provost D, Whitten CW. Anesthetic considerations for bariatric surgery. Anesth Analg. 2002 Dec;95(6):1793–805. https://doi.org/10.1097/00000539-200212000-00061 PMID:12456461
Meretoja OA. Neuromuscular block and current treatment strategies for its reversal in children. Paediatr Anaesth. 2010 Jul;20(7):591–604. https://doi.org/10.1111/j.1460-9592.2010.03335.x PMID:20642658
Chassard D, Bryssine B, Golfier F, Raupp C, Raudrant D, Boulétreau P. [Gynecologic laparoscopy with or without curare]. Ann Fr Anesth Reanim. 1996;15(7):1013–7. https://doi.org/10.1016/S0750-7658(96)89470-6 PMID:9180976
Rossiter JD, Wood M, Lockwood A, Lewis K. Operating conditions for ocular surgery under general anaesthesia: an eccentric problem. Eye (Lond). 2006 Jan;20(1):55–8. https://doi.org/10.1038/sj.eye.6701789 PMID:15650757
Chui PT, Gin T, Oh TE. Anaesthesia for laparoscopic general surgery. Anaesth Intensive Care. 1993 Apr;21(2):163–71. PMID:8517506
Welliver M, McDonough J, Kalynych N, Redfern R. Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent. Drug Des Devel Ther. 2009 Feb;2:49–59. PMID:19920893
Mencke T, Echternach M, Kleinschmidt S, Lux P, Barth V, Plinkert PK et al. Laryngeal morbidity and quality of tracheal intubation: a randomized controlled trial. Anesthesiology. 2003 May;98(5):1049–56. https://doi.org/10.1097/00000542-200305000-00005 PMID:12717124
Murphy GS. Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anestesiol. 2006 Mar;72(3):97–109. PMID:16493386
Eikermann M, Blobner M, Groeben H, Rex C, Grote T, Neuhäuser M et al. Postoperative upper airway obstruction after recovery of the train of four ratio of the adductor pollicis muscle from neuromuscular blockade. Anesth Analg. 2006 Mar;102(3):937–42. https://doi.org/10.1213/01.ane.0000195233.80166.14 PMID:16492855
Berg H, Roed J, Viby-Mogensen J, Mortensen CR, Engbaek J, Skovgaard LT et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand. 1997 Oct;41(9):1095–103. https://doi.org/10.1111/j.1399-6576.1997.tb04851.x PMID:9366929
Bissinger U, Schimek F, Lenz G. Postoperative residual paralysis and respiratory status: a comparative study of pancuronium and vecuronium. Physiol Res. 2000;49(4):455–62. PMID:11072806
Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LI. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology. 2000 Apr;92(4):977–84. https://doi.org/10.1097/00000542-200004000-00014 PMID:10754616
Gätke MR, Viby-Mogensen J, Rosenstock C, Jensen FS, Skovgaard LT. Postoperative muscle paralysis after rocuronium: less residual block when acceleromyography is used. Acta Anaesthesiol Scand. 2002 Feb;46(2):207–13. https://doi.org/10.1034/j.1399-6576.2002.460216.x PMID:11942873
Hayes AH, Mirakhur RK, Breslin DS, Reid JE, McCourt KC. Postoperative residual block after intermediate-acting neuromuscular blocking drugs. Anaesthesia. 2001 Apr;56(4):312–8. https://doi.org/10.1046/j.1365-2044.2001.01921.x PMID:11284816
Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003 May;98(5):1042–8. https://doi.org/10.1097/00000542-200305000-00004 PMID:12717123
Baillard C, Clec’h C, Catineau J, Salhi F, Gehan G, Cupa M et al. Postoperative residual neuromuscular block: a survey of management. Br J Anaesth. 2005 Nov;95(5):622–6. https://doi.org/10.1093/bja/aei240 PMID:16183681
Cammu G, De Witte J, De Veylder J, Byttebier G, Vandeput D, Foubert L et al. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg. 2006 Feb;102(2):426–9. https://doi.org/10.1213/01.ane.0000195543.61123.1f PMID:16428537
Viby-Mogensen J. Poglavje 39. Neuromuscular Monitoring. V: Miller’s Anesthesia. Philadelphia: Elsevier; 2005. pp. 1551–69.
Kopman AF. Neuromuscular monitoring: old issues, new controversies [Fuchs-Buder T, Claudius C, Skovgaard LT]. J Crit Care. 2009 Mar;24(1):11–20. https://doi.org/10.1016/j.jcrc.2008.02.008 PMID:19272534
Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J; 8th International Neuromuscular Meeting. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007 Aug;51(7):789–808. https://doi.org/10.1111/j.1399-6576.2007.01352.x PMID:17635389
WATAG: Sugammadex Guidelines- July 2013.
Kopman AF, Eikermann M. Antagonism of non-depolarising neuromuscular block: current practice. Anaesthesia. 2009 Mar;64 Suppl 1:22–30. https://doi.org/10.1111/j.1365-2044.2008.05867.x PMID:19222428
White PF, Tufanogullari B, Sacan O, Pavlin EG, Viegas OJ, Minkowitz HS et al. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex. Anesth Analg. 2009 Mar;108(3):846–51. https://doi.org/10.1213/ane.0b013e31818a9932 PMID:19224792
Jones KR, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugamadex. Anesthesiology. 2008;109(5):816–24. https://doi.org/10.1097/ALN.0b013e31818a3fee PMID:18946293
Ledowski T. Sugammadex: what do we know and what do we still need to know? A review of the recent (2013 to 2014) literature. Anaesth Intensive Care. 2015 Jan;43(1):14–22. PMID:25579285
Schaller SJ, Fink H. Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core Evid. 2013;8:57–67. PMID:24098155
Bisschops MM, Holleman C, Huitink JM. Can sugammadex save a patient in a simulated ‘cannot intubate, cannot ventilate’ situation? Anaesthesia. 2010 Sep;65(9):936–41. https://doi.org/10.1111/j.1365-2044.2010.06455.x PMID:21198485
Ackerman AG, Russ S, Puttick N, Kessell G. Availability and storage of sugammadex for emergency use. Anaesthesia. 2011 Feb;66(2):139–40. https://doi.org/10.1111/j.1365-2044.2010.06595.x PMID:21254994
Kim YH. Repeat dosing of rocuronium-sugammadex: unpredictable. Korean J Anesthesiol. 2014 Jul;67(1):1–3. https://doi.org/10.4097/kjae.2014.67.1.1 PMID:25097730
Fabregat-López J, Veiga-Ruiz G, Dominguez-Serrano N, García-Martinez MR. Re-establishment of neuromuscular block by rocuronium after sugammadex administration. Can J Anaesth. 2011 Jul;58(7):658–9. https://doi.org/10.1007/s12630-011-9499-1 PMID:21468657
Dierdorf SF, Scott Walton J, Stasic AF. Rare Coexisting Diseases. In: Barash PG et al., editors. Clinical anesthesia. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. pp. 612–40.
Fleisher LA, Mythen M. Anesthetic Implications of Concurrent Diseases. In: Miller RD et al., editors. Miller’s Anesthesia. 8th ed. Philadelphia: Elsevier Saunders; 2015. pp. 1156–225.
Schaller SJ, Fink H. Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core Evid. 2013;8:57–67. PMID:24098155
Lobaz S, Clymer M, Sammut M. Safety and Efficacy of Sugammadex for Neuromuscular Blockade Reversal. Clin Med Insights Ther. 2014;6:1–14. https://doi.org/10.4137/CMT.S10241.
de Boer HD, van Esmond J, Booij LH, Driessen JJ. Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy. Paediatr Anaesth. 2009 Dec;19(12):1226–8. https://doi.org/10.1111/j.1460-9592.2009.03178.x PMID:19863737
Baumgartner P. Rocuronium and sugammadex in myotonic dystrophy. Anaesth Intensive Care. 2010 Sep;38(5):959–60. PMID:20865895
Suzuki T, Nameki K, Shimizu H, Shimizu Y, Nakamura R, Ogawa S. Efficacy of rocuronium and sugammadex in a patient with dermatomyositis. Br J Anaesth. 2012 Apr;108(4):703. https://doi.org/10.1093/bja/aes087 PMID:22419633
Petrun AM, Mekis D, Kamenik M. Successful use of rocuronium and sugammadex in a patient with myasthenia. Eur J Anaesthesiol. 2010 Oct;27(10):917–8. https://doi.org/10.1097/EJA.0b013e3283392593 PMID:20375901
Unterbuchner C, Fink H, Blobner M. The use of sugammadex in a patient with myasthenia gravis. Anaesthesia. 2010 Mar;65(3):302–5. https://doi.org/10.1111/j.1365-2044.2009.06236.x PMID:20105151
de Boer HD, van Egmond J, Driessen JJ, Booij LH. Sugammadex in patients with myasthenia gravis. Anaesthesia. 2010 Jun;65(6):653. https://doi.org/10.1111/j.1365-2044.2010.06360.x PMID:20565409
Vymazal T, Krecmerova M, Bicek V, Lischke R. Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery - a series of 117 cases. Ther Clin Risk Manag. 2015 Oct;11:1593–6. https://doi.org/10.2147/TCRM.S93009 PMID:26508869
Stewart PA, Phillips S, De Boer HD. Sugammadex reversal of rocuronium-induced neuromuscular blockade in two types of neuromuscular disorders: myotonic dystrophy and spinal muscular atrophy. Rev Esp Anestesiol Reanim. 2013 Apr;60(4):226–9. https://doi.org/10.1016/j.redar.2012.07.007 PMID:22947194
Vilela H, Santos J, Colaço J, Oliveira E, Canas-da-Silva P. Reversal of neuromuscular blockade with sugammadex in a patient with spinal muscular atrophy type III (Kugelberg-Welander syndrome). J Anesth. 2012 Apr;26(2):306–7. https://doi.org/10.1007/s00540-011-1308-z PMID:22198219
Kelsaka E, Karakaya D, Zengin EC. Use of sugammadex in a patient with amyotrophic lateral sclerosis. Med Princ Pract. 2013;22(3):304–6. https://doi.org/10.1159/000343168 PMID:23075763
Khan MH, Banerjee A. Anaesthesia and orphan disease: sugammadex in a patient with Huntington’s disease undergoing thyroid lobectomy. Eur J Anaesthesiol. 2012 Dec;29(12):593–5. https://doi.org/10.1097/EJA.0b013e328356472a PMID:22935957
Jakubiak J, Gaszyński T, Gaszyński W. Neuromuscular block reversal with sugammadex in a morbidly obese patient with myasthenia gravis. Anaesthesiol Intensive Ther. 2012 Jan-Mar;44(1):28–30. PMID:23801510
Stourac P, Krikava I, Seidlova J, Strazevska E, Huser M, Hruban L et al. Sugammadex in a parturient with myotonic dystrophy. Br J Anaesth. 2013 Apr;110(4):657–8. https://doi.org/10.1093/bja/aet037 PMID:23508494
Sungur Z, Sentürk M. Anaesthesia for thymectomy in adult and juvenile myasthenic patients. Curr Opin Anaesthesiol. 2016 Feb;29(1):14–9. https://doi.org/10.1097/ACO.0000000000000272 PMID:26545147
Fujita A, Ishibe N, Yoshihara T, Ohashi J, Makino H, Ikeda M et al. Rapid reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients with liver dysfunction undergoing hepatic surgery. Acta Anaesthesiol Taiwan. 2014 Jun;52(2):54–8. https://doi.org/10.1016/j.aat.2014.04.007 PMID:25016508
Welliver M, Cheek D, Osterbrink J, McDonough J. Worldwide experience with sugammadex sodium: implications for the United States. AANA J. 2015 Apr;83(2):107–15. PMID:26016169
Ezri T, Boaz M, Sherman A, Armaly M, Berlovitz Y. Sugammadex: an update. JCCM. 2016;2:16–21.
de Souza CM, Tardelli MA, Tedesco H, Garcia NN, Caparros MP, Alvarez-Gomez JA et al. Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: A comparative prospective clinical trial. Eur J Anaesthesiol. 2015 Oct;32(10):681–6. https://doi.org/10.1097/EJA.0000000000000312 PMID:26225497
Panhuizen IF, Gold SJ, Buerkle C, Snoeck MM, Harper NJ, Kaspers MJ et al. Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment. Br J Anaesth. 2015 May;114(5):777–84. https://doi.org/10.1093/bja/aet586 PMID:25829395
Tsur A, Kalansky A. Hypersensitivity associated with sugammadex administration: a systematic review. Anaesthesia. 2014 Nov;69(11):1251–7. https://doi.org/10.1111/anae.12736 PMID:24848211
Takazawa T, Mitsuhata H, Mertes PM. Sugammadex and rocuronium-induced anaphylaxis. J Anesth. 2016 Apr;30(2):290–7. https://doi.org/10.1007/s00540-015-2105-x PMID:26646837
Simons FE, Ardusso LR, Bilò MB, El-Gamal YM, Ledford DK, Ring J et al.; World Allergy Organization. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011 Feb;4(2):13–37. https://doi.org/10.1097/WOX.0b013e318211496c PMID:23268454
Leysen J, Bridts CH, De Clerck LS, Vercauteren M, Lambert J, Weyler JJ et al. Allergy to rocuronium: from clinical suspicion to correct diagnosis. Allergy. 2011 Aug;66(8):1014–9. https://doi.org/10.1111/j.1398-9995.2011.02569.x PMID:21375539
Barthel F, Stojeba N, Lyons G, Biermann C, Diemunsch P. Sugammadex in rocuronium anaphylaxis: dose matters. Br J Anaesth. 2012 Oct;109(4):646–7. https://doi.org/10.1093/bja/aes332 PMID:22976863
Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003 May;98(5):1042–8. https://doi.org/10.1097/00000542-200305000-00004 PMID:12717123
Baillard C, Clec’h C, Catineau J, Salhi F, Gehan G, Cupa M et al. Postoperative residual neuromuscular block: a survey of management. Br J Anaesth. 2005 Nov;95(5):622–6. https://doi.org/10.1093/bja/aei240 PMID:16183681
Cammu G, De Witte J, De Veylder J, Byttebier G, Vandeput D, Foubert L et al. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg. 2006 Feb;102(2):426–9. https://doi.org/10.1213/01.ane.0000195543.61123.1f PMID:16428537
Fuchs-Buder T. The use of sugammadex in clinical practice: which patients are most likely to benefit? Curr Anesthesiol Rep. 2016;6(2):185–91. https://doi.org/10.1007/s40140-016-0157-6.
Farooq K, Hunter JM. Neuromuscular blocking agents and reversal agents. Anaesth Intensive Care Med. 2014;15(6):295–9. https://doi.org/10.1016/j.mpaic.2014.03.011.
Carron M, Zarantonello F, Tellaroli P, Ori C. Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. J Clin Anesth. 2016 Dec;35:1–12. https://doi.org/10.1016/j.jclinane.2016.06.018 PMID:27871504
Copyright (c) 2018 Slovenian Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
